...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >In vivo cross-protection to African horse sickness Serotypes 5 and 9 after vaccination with Serotypes 8 and 6
【24h】

In vivo cross-protection to African horse sickness Serotypes 5 and 9 after vaccination with Serotypes 8 and 6

机译：接种8号和6号血清后对非洲5号和9号马疾病的体内交叉保护

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The polyvalent African horsesickness (AHS) attenuated live virus (AHS-ALV) vaccine produced at Onderstepoort Biological Products incorporates 7 of the 9 known serotypes circulating in southern Africa. Serological cross-reaction has been shown in vitro to Serotypes 5 and 9 by Serotypes 8 and 6 respectively, but the degree of in vivo cross-protection between these serotypes in vaccinated horses has not previously been reported. Due to the increasing incidence of AHS Serotypes 5 and 9 in the field, over the last 3-4 seasons of AHS in South Africa, and the absence of Serotypes 5 and 9 in the AHS-ALV vaccine, it was necessary to conduct a vaccination-challenge study to determine in vivo cross-protection of vaccine-incorporated Serotypes 8 and 6 respectively. Groups of horses were vaccinated with either the polyvalent AHS-ALV vaccine or a monovalent Serotype 6 (vAHSV6) or 8 (vAHSV8) vaccine to determine the cross-protection of vaccinated horses following challenge with virulent AHS virus (AHSV) of either Serotype 5, 6, 8 or 9. Serial vaccination of naive horses with the polyvalent AHS-ALV vaccine generated a broad neutralizing antibody response to all vaccine strains as well as cross-neutralizing antibodies to Serotypes 5 and 9. Booster vaccination of horses with monovalent vaccine vAHSV6 or vAHSV8 induced an adequate protective immune response to challenge with homologous and heterologous virulent virus. In vivo cross-protection between AHSV6 and AHSV9 and AHSV8 and AHSV5 respectively, was demonstrated
机译：Onderstepoort生物制品公司生产的多价非洲晕车（AHS）减毒活病毒（AHS-ALV）疫苗包含了在南部非洲流通的9种已知血清型中的7种。血清型8和6分别在体外显示出与血清型5和9的血清学交叉反应，但是以前没有报道过接种马匹中这些血清型之间的体内交叉保护程度。由于南非AHS血清型5和9在过去的3-4个季节在现场的发病率不断增加，并且AHS-ALV疫苗中没有血清型5和9，因此有必要进行疫苗接种-挑战研究，以确定分别与疫苗结合的血清型8和6的体内交叉保护。使用多价AHS-ALV疫苗或单价6型血清型（vAHSV6）或8型（vAHSV8）疫苗对马组进行免疫接种，以确定在用5型血清型的强力AHS病毒攻击后接种的马的交叉保护。 6、8或9。使用多价AHS-ALV疫苗对幼稚马进行连续疫苗接种可产生对所有疫苗株的广泛中和抗体反应，以及针对血清型5和9的交叉中和抗体。用单价疫苗vAHSV6或vAHSV8诱导了足够的保护性免疫应答，以攻击同源和异源强毒病毒。分别在AHSV6和AHSV9与AHSV8和AHSV5之间进行了体内交叉保护

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号